(Q35032056)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

R M Weinshilboum

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Pharmacometabolomics Research Network

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

5 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

154-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

Genetic Control of Drug Levels in Man: Antipyrine

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Genetic control of dicumarol levels in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacogenomics: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacogenetics and pharmacogenomics: development, science, and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics: a global biochemical approach to drug response and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabolomics reveals racial differences in response to atenolol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabonomics as an effector for personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabonomics and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics in toxicology: preclinical and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics: a global biochemical approach to the study of central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Innovation: Metabolomics: the apogee of the omics trilogy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolic phenotyping in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomic analysis and signatures in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Associations between purine metabolites and clinical symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Opioid use affects antioxidant activity and purine metabolism: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Alterations in metabolic pathways and networks in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Liquid chromatography-mass spectrometry based global metabolite profiling: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Stable isotope-resolved metabolomics and applications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Targeting aspartate aminotransferase in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabolomics of statin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Neuropsychopharmacology and the affective disorders. (Third of three parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Genomewide association studies: history, rationale, and prospects for psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

The neuronal transporter gene SLC6A15 confers risk to major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

A genomewide association study of citalopram response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomics tools for identifying biomarkers for neuropsychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

A preliminary metabolomic analysis of older adults with and without depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomic differences in heart failure patients with and without major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Metabolomic mapping of atypical antipsychotic effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Serum molecular signatures of weight change during early breast cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

A map of human genome variation from population-scale sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmaco-metabonomic phenotyping and personalized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Enteric microbiome metabolites correlate with response to simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Systems biology and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabonomic Characterization of Xenobiotic and Endogenous Metabolic Phenotypes That Account for Inter-individual Variation in Isoniazid-Induced Toxicological Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Pharmacometabonomic Investigation of Dynamic Metabolic Phenotypes Associated with Variability in Response to Galactosamine Hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

Images in clinical medicine. Acute mesenteric infarction associated with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

7 January 2021

Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

7 January 2021

Depressive disease. Evidence favoring polygenic inheritance based on an analysis of ancestral cases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

7 January 2021

Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

7 January 2021

Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.217

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24193171%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference